Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dna X (SONM) Common Equity (2018 - 2025)

Historic Common Equity for Dna X (SONM) over the last 8 years, with Q3 2025 value amounting to -$701000.0.

  • Dna X's Common Equity fell 10456.71% to -$701000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$701000.0, marking a year-over-year decrease of 10456.71%. This contributed to the annual value of -$5.7 million for FY2024, which is 12548.28% down from last year.
  • As of Q3 2025, Dna X's Common Equity stood at -$701000.0, which was down 10456.71% from -$1.3 million recorded in Q2 2025.
  • Dna X's Common Equity's 5-year high stood at $23.1 million during Q3 2023, with a 5-year trough of -$5.7 million in Q4 2024.
  • Over the past 5 years, Dna X's median Common Equity value was $17.5 million (recorded in 2024), while the average stood at $13.4 million.
  • Per our database at Business Quant, Dna X's Common Equity soared by 20874.22% in 2023 and then tumbled by 12548.28% in 2024.
  • Dna X's Common Equity (Quarter) stood at $18.6 million in 2021, then rose by 7.6% to $20.0 million in 2022, then rose by 11.59% to $22.4 million in 2023, then crashed by 125.48% to -$5.7 million in 2024, then surged by 87.7% to -$701000.0 in 2025.
  • Its last three reported values are -$701000.0 in Q3 2025, -$1.3 million for Q2 2025, and -$1.1 million during Q1 2025.